about
Lack of effects of typical and atypical antipsychotics in DARPP-32 and NCS-1 levels in PC12 cells overexpressing NCS-1Early interventions to prevent psychosis: systematic review and meta-analysisQuestioning an axiom: better prognosis for schizophrenia in the developing world?Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychosesAripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychosesCognitive behavioural therapy (brief versus standard duration) for schizophreniaTai chi for schizophreniaCognitive behavioural therapy (brief versus standard duration) for schizophreniaInformation and communication technology in patient education and support for people with schizophreniaZuclopenthixol acetate for acute schizophrenia and similar serious mental illnessesCognitive behaviour therapy (brief versus standard duration) for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaMemantine for schizophreniaBromperidol decanoate (depot) for schizophreniaCognitive behaviour therapy (group) for schizophreniaAcetylcholinesterase inhibitors for schizophreniaClozapine dose for schizophreniaAllopurinol and related drugs for schizophreniaBromperidol decanoate (depot) for schizophreniaClozapine versus other atypical antipsychotics for schizophreniaAcetylcholinesterase inhibitors for schizophreniaCulture, stress and recovery from schizophrenia: lessons from the field for global mental healthOmega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsA Role for Estrogen in Schizophrenia: Clinical and Preclinical FindingsMetacognitive training for schizophrenia: a systematic reviewToward developmental models of psychiatric disorders in zebrafishReview of the evidence: prevalence of medical conditions in the United States population with serious mental illnessThe neuroimmunology of schizophreniaQuality of medical care for persons with serious mental illness: A comprehensive reviewKnockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesA frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorderNew challenges in family interventions for schizophreniaSystematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene databaseDownregulation of the cAMP/PKA pathway in PC12 cells overexpressing NCS-1Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?
P2860
Q21245639-FF6BF68B-D4A3-48B4-AF66-972212FB3E96Q22242061-3979105E-F51E-4C36-A265-433ED049BD90Q22242830-45470FCE-9127-4CE9-8EC5-6ED825503B6FQ24186218-9997F995-91D1-41C6-B6E3-1DFE67DBCE91Q24186219-F7B492AF-6DB6-44E6-9823-9E17F2A9C9AEQ24186220-49420024-51FA-47BA-83D6-FF337213B4E6Q24186223-88FD09C4-2E4A-4162-9FB2-7F0028F91FF1Q24186426-717F227B-A723-4AF9-B499-3DAA75FEF902Q24186914-C723E366-EED8-49F5-8ABE-1F56E09295DFQ24195092-D00DDC52-6B18-4E20-847B-AB60F96C91A1Q24198042-E7FB4FB7-F277-4C6E-A717-C5AD78AEE43FQ24200306-E57C8CC9-88AC-44E5-8031-5B3B19A76D73Q24201634-9AE644CE-1AD2-4A1C-9F70-8C2698AF243DQ24202427-19D0C5E9-70DA-4DC7-A831-055435AE1305Q24202544-A4017D2F-94D3-4072-89BC-1589D484F21EQ24202780-930C6B26-C20A-4216-B766-1D00BB5DD0EEQ24203825-FAD6CA81-47AB-496C-98FD-EF3A9E1BC202Q24203876-53989CE4-8BFF-4913-97E5-FED6AB717D7EQ24203938-E6EE6A33-25F6-44AF-8166-84795E9B1645Q24203967-B4170E99-6BAC-47C5-B42D-40349EA058C6Q24234287-A57C1173-D73B-4DEF-812E-4E0649FCD8ACQ24236422-AA3DB003-C879-4FC9-9A2A-DC25796DD248Q24240611-82CDE7AC-C31A-451C-A843-7F6A50299FABQ24629220-792A5754-7FEE-4BE0-8CA6-1938DD33B70FQ24681087-19271264-F5AF-4436-A127-F1EB3930AE80Q25256710-E52196A8-F2A2-4043-BFD1-250057C1AC86Q26744729-0135A885-854B-4339-BEE2-0C5F81075AD7Q26778420-9594C47F-A8F7-483F-8C79-BB2B05F37BE0Q26795574-83D2A995-551F-467B-9A8F-4797B3517321Q26830848-E6293F1F-192F-45B3-99B5-FA1384770367Q26849474-97F0958C-EDF3-4EAE-AD61-1F8B569346ADQ26859392-600BC099-26E0-4575-87BD-D034119F927DQ27026165-9B9789AB-E5E7-4B69-B681-ABAF4829D375Q27338525-F7123A3A-DF0B-4484-A9CD-061CD5BDF5D1Q28072353-B6330FBD-D445-4E4F-A5F2-DD5F886B1626Q28254976-1C665D78-10AC-4B0C-981F-3EE2C38C7ACAQ28280498-316A689B-DFB8-4C54-A021-2A6DA7048656Q28285397-78A7FB62-654F-42CA-BA79-12212B90A3ADQ28293208-92056EBD-38C1-4435-BB05-0CCFA2B7C218Q28303348-361C911E-B322-4166-B32C-ABADB921BCDB
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Schizophrenia
@ast
Schizophrenia
@en
Schizophrenia
@nl
type
label
Schizophrenia
@ast
Schizophrenia
@en
Schizophrenia
@nl
prefLabel
Schizophrenia
@ast
Schizophrenia
@en
Schizophrenia
@nl
P3181
P1433
P1476
Schizophrenia
@en
P2093
Kim T Mueser
Susan R McGurk
P304
P3181
P356
10.1016/S0140-6736(04)16458-1
P407
P577
2004-06-19T00:00:00Z